Drug intelligence / Profile preview

Yinxieping tablets

Development stage: Unknown
Lead developer: Shaanxi Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Yinxieping tablets is a Traditional Chinese Medicine (TCM) botanical formulation developed by the Shaanxi Traditional Chinese Medicine Hospital for the treatment of psoriasis vulgaris. It is primarily indicated for patients with mild to moderate psoriasis. The drug is designed based on TCM theories to address blood-heat and wind-dryness patterns common in psoriatic conditions. It has been evaluated in multicenter, randomized, double-blind, placebo-controlled clinical trials in China to establish its therapeutic efficacy and safety profile.

Brand names: Yinxieping tablets
Other names: Yinxieping pian银屑平片

Beyond the preview

Go deeper on Yinxieping tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yinxieping tablets.

Explore the full profile